Optimal ELF cutoffs identify significant fibrosis and cirrhosis in patients with MASLDNew test cutoffs help identify liver scarring in fatty liver disease

Alimentary pharmacology & therapeutics Published October 2, 2026 Study authors: Gee Matthew F W, Chalfin Donald B, De Vol Edward B, Levy H Roma, Boltyenkov Artem T, Casale Mario Gu… PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Use ELF cutoffs of 9.00, 9.80, and 10.50 to guide fibrosis staging and anti-fibrotic treatment decisions in MASLD.

This meta-analysis evaluates the performance of the Enhanced Liver Fibrosis (ELF) Test in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The analysis synthesized data from 37 cohorts across 34 studies to determine optimal cutoffs for identifying significant fibrosis (≥F2), advanced fibrosis (≥F3), and cirrhosis (F4).

The study identified Youden cutoffs of 9.37 (AUROC 0.818) for ≥F2, 9.64 (AUROC 0.818) for ≥F3, and 9.99 (AUROC 0.774) for F4. Evaluation of established cutoffs showed that an ELF of 9.00 provided 0.86 sensitivity and 0.61 specificity for ≥F2, while 9.80 provided 0.70 sensitivity and 0.79 specificity for ≥F3. For F4, an ELF of 11.30 yielded 0.21 sensitivity and 0.96 specificity, while 10.50 yielded 0.50 sensitivity and 0.86 specificity.

Clinically, the authors suggest that an ELF < 9.00 may be useful to rule out ≥F2 fibrosis. They note that ELF ≥ 9.80 and ≥ 11.30 represent balanced cutoffs for ≥F3 and F4, respectively. Additionally, an ELF ≥ 10.50 may serve as an upper limit for MASLD-related anti-fibrotic therapeutic decision-making. The authors note that an ELF of 7.70 is not a meaningful cutoff for any purpose.

How this fits prior evidence

This meta-analysis addresses a gap in identifying specific diagnostic thresholds for fibrosis in MASLD. While prior evidence has identified factors like macrophage metabolic reprogramming and gut-liver axis breakdown as drivers of liver injury in MASLD, this study provides specific ELF test cutoffs to quantify fibrosis. These cutoffs may assist in managing the progression of MASLD in various populations, including those with HIV or pediatric cases.

Living with metabolic dysfunction-associated steatotic liver disease (MASLD) means managing a condition where fat builds up in the liver. A major concern for patients is the development of fibrosis, which is the scarring of liver tissue. Identifying exactly how much scarring has occurred is vital for making the right treatment decisions.

Researchers analyzed 37 different groups to find the best scores for the Enhanced Liver Fibrosis (ELF) test. This test helps doctors see how much damage is happening. The study found that specific scores, called cutoffs, can help identify different stages of scarring. For example, a score of 9.80 or higher helps identify advanced scarring, while a score of 11.30 helps identify cirrhosis, which is severe scarring.

While the test is a helpful tool, it is not perfect. Some scores are better at ruling out early scarring, while others are better at confirming advanced stages. These specific numbers help doctors decide when to start more intensive treatments for liver damage. Talk to your doctor to see how these test results apply to your specific health needs.

What this means for you:

Specific ELF test scores help doctors identify the severity of liver scarring in patients with fatty liver disease.

Common questions

What is the ELF test used for?

The Enhanced Liver Fibrosis (ELF) test is used to identify different stages of liver scarring, known as fibrosis. It helps doctors see if a patient has significant fibrosis (F2), advanced fibrosis (F3), or cirrhosis (F4) in those with metabolic dysfunction-associated steatotic liver disease.

How do the different ELF scores help doctors?

Different scores, or cutoffs, help identify different levels of damage. A score below 9.00 can help rule out significant scarring. Scores of 9.80 and 11.30 are balanced for identifying advanced stages. A score of 10.50 can help doctors decide when to start specific treatments to fight liver scarring.

Is the ELF test accurate for all stages?

The test's accuracy depends on the specific score used. For example, a score of 9.80 has 70% sensitivity for advanced fibrosis, while a score of 11.30 has a very low 21% sensitivity for cirrhosis. Because results vary, you should discuss these specific numbers with your doctor.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedOct 2026

PMID42638152

View Original Abstract ↓

BACKGROUND: Non-invasive tests are increasingly employed to evaluate liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease (MASLD). Accurate cutoffs for significant fibrosis (≥F2), advanced fibrosis (≥F3), and cirrhosis (F4) are critical for establishing diagnostic guidelines and qualification for MASLD-related anti-fibrotic therapy. AIMS: Determine optimal Enhanced Liver Fibrosis (ELF) Test MASLD cutoffs for ≥F2, ≥F3, and F4 identification and decision-making, evaluate the appropriateness of guideline-recommended cutoffs, and assess ELF performance. METHODS: Using four databases, we identified 34 MASLD-focused studies conducted between 2004 and 2026 evaluating ELF cutoffs (37 cohorts): quality was assessed using Quality Assessment of Diagnostic Accuracy Studies version 2 (QUADAS-2). Multiple cutoffs were integrated using hierarchical summary receiver operating characteristic analysis. Sensitivity (Sens) and specificity (Spec) at Youden cutoffs and guideline-recommended cutoffs were estimated using Steinhauser's hierarchical multi-cutoff random-effects model and R diagmeta package v0.5-1. RESULTS: Youden cutoffs (AUROCs [95% CIs]) were: ≥F2: 9.37 (0.818 [0.781-0.850]); ≥F3: 9.64 (0.818 [0.782-0.850]); F4: 9.99 (0.774 [0.711-0.827]). Sens and Spec at established cutoffs were: ≥F2 (9.00) 0.86 Sens, 0.61 Spec; ≥F3 (9.80) 0.70 Sens, 0.79 Spec; F4 (11.30) 0.21 Sens, 0.96; and F4 (10.50) 0.50 Sens, 0.86 Spec. For F2 rule-out (7.70), Sens = 0.98 and Spec = 0.14. CONCLUSION: ELF < 9.00 may be useful to rule out ≥ F2 fibrosis in MASLD. ELF ≥ 9.80 and ≥ 11.30 represent balanced cutoffs for ≥F3 and F4 fibrosis, respectively. ELF ≥ 10.50 could represent an upper limit for MASLD-related anti-fibrotic therapeutic decision-making. ELF at 7.70 is not a meaningful cutoff for any purpose. TRIAL REGISTRATION: PROSPERO registration: CRD420251145859.

Optimal ELF cutoffs identify significant fibrosis and cirrhosis in patients with MASLDNew test cutoffs help identify liver scarring in fatty liver disease

How this fits prior evidence

Common questions

Study Details

Higher TyG Index Linked to 4.36-Fold Increased Odds of NAFLD in Large Meta-Analysis

TyG Index Linked to Higher Fatty Liver Risk

Clinical research that matters. Delivered to your inbox.

Optimal ELF cutoffs identify significant fibrosis and cirrhosis in patients with MASLDNew test cutoffs help identify liver scarring in fatty liver disease

How this fits prior evidence

Common questions

More on Metabolic Dysfunction-Associated Steatotic Liver Disease

Study Details

Higher TyG Index Linked to 4.36-Fold Increased Odds of NAFLD in Large Meta-Analysis

TyG Index Linked to Higher Fatty Liver Risk

Clinical research that matters. Delivered to your inbox.

Related in Gastroenterology

From Other Specialties